Long-term results after neoadjuvant radiochemotherapy for locally advanced resectable extraperitoneal rectal cancer

被引:46
|
作者
Coco, C
Valentini, V
Manno, A
Mattana, C
Verbo, A
Cellini, N
Gambacorta, MA
Covino, M
Mantini, G
Miccichè, F
Pedretti, G
Petito, L
Rizzo, G
Cosimelli, M
Impiombato, FA
Picciocchi, A
机构
[1] Univ Sacred Heart, Poclin A Gemelli, Dept Surg, I-00168 Rome, Italy
[2] Univ Sacred Heart, Dept Radiat Therapy, I-00168 Rome, Italy
[3] Univ Sacred Heart, Dept Emergency Med, I-00168 Rome, Italy
[4] Ist Nazl Tumori Regina Elena, Dept Surg, Rome, Italy
[5] Ist Nazl Tumori Regina Elena, Dept Radiat Therapy, Rome, Italy
关键词
rectal cancer; preoperative radiochemotherapy; combined modality therapy;
D O I
10.1007/s10350-005-0291-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose: This study was designed to evaluate long-term outcome in locally advanced resectable extraperitoneal rectal cancer treated by preoperative radiochemotherapy. Methods: Eighty-three consecutive patients who developed locally advanced resectable extraperitoneal rectal cancer underwent preoperative concomitant radiochemotherapy followed by surgery, including total mesorectal excision. Results: Median follow-up was 108 (range, 10-169) months. The living patients underwent complete follow-up of, at least, nine years. Fourteen patients developed local recurrence. The time to detection was longer than two years in eight cases and longer than five years in four. Twenty-one patients developed metastases, 19 within the first five years from surgery. At the univariate analysis, clinical stage at presentation, lymph node involvement at clinical restaging after neoadjuvant therapy, and pTand pN stage were found positively correlated to the incidence of metastases. At the multivariate analysis, the only factors which confirmed a positive correlation were pT stage and pN stage. The actuarial overall survival at five, seven, and ten years was 75.5, 67.8, and 60.4 percent, respectively. The same figures for cancer-related survival were 77.9, 70, and 65.8 percent. At the univariate analysis, factors directly correlated with worse survival were: TNM stage at clinical restaging after neoadjuvant therapy (in particular lymph node involvement) pTNM, pT, and pN. At the multivariate analysis the only factors that confirmed a correlation with worse survival were pTNM, pT, and pN. Conclusions: Long- term follow-up allows to individuate 28 percent of all local relapses after the first five years from surgery. Postoperative stage is highly predictive of prognosis.
引用
收藏
页码:311 / 318
页数:8
相关论文
共 50 条
  • [21] Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome
    Antonio Avallone
    Luigi Aloj
    Corradina Caracò
    Paolo Delrio
    Biagio Pecori
    Fabiana Tatangelo
    Nigel Scott
    Rossana Casaretti
    Francesca Di Gennaro
    Massimo Montano
    Lucrezia Silvestro
    Alfredo Budillon
    Secondo Lastoria
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 1848 - 1857
  • [22] Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome
    Avallone, Antonio
    Aloj, Luigi
    Caraco, Corradina
    Delrio, Paolo
    Pecori, Biagio
    Tatangelo, Fabiana
    Scott, Nigel
    Casaretti, Rossana
    Di Gennaro, Francesca
    Montano, Massimo
    Silvestro, Lucrezia
    Budillon, Alfredo
    Lastoria, Secondo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (12) : 1848 - 1857
  • [23] Laparoscopic total mesorectal excision for extraperitoneal rectal cancer: Long-term results
    Jacopo Martellucci
    Carlo Bergamini
    Alessandro Bruscino
    Paolo Prosperi
    Pietro Tonelli
    Antonio Todaro
    Andrea Valeri
    International Journal of Colorectal Disease, 2014, 29 : 1493 - 1499
  • [24] Laparoscopic total mesorectal excision for extraperitoneal rectal cancer: Long-term results
    Martellucci, Jacopo
    Bergamini, Carlo
    Bruscino, Alessandro
    Prosperi, Paolo
    Tonelli, Pietro
    Todaro, Antonio
    Valeri, Andrea
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2014, 29 (12) : 1493 - 1499
  • [25] Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer
    Vaneja Velenik
    Irena Oblak
    Franc Anderluh
    Radiation Oncology, 5
  • [26] Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial
    Akihiro Tomida
    Keisuke Uehara
    Kazuhiro Hiramatsu
    Atsuyuki Maeda
    Eiji Sakamoto
    Yoshito Okada
    Yasuhiro Kurumiya
    Goro Nakayama
    Masanao Nakamura
    Toshisada Aiba
    Masato Nagino
    International Journal of Clinical Oncology, 2019, 24 : 403 - 410
  • [27] Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial
    Tomida, Akihiro
    Uehara, Keisuke
    Hiramatsu, Kazuhiro
    Maeda, Atsuyuki
    Sakamoto, Eiji
    Okada, Yoshito
    Kurumiya, Yasuhiro
    Nakayama, Goro
    Nakamura, Masanao
    Aiba, Toshisada
    Nagino, Masato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (04) : 403 - 410
  • [28] Prognostic significance of tumor regression in locally advanced rectal cancer after preoperative radiochemotherapy
    Omejc, Mirko
    Potisek, Maja
    RADIOLOGY AND ONCOLOGY, 2018, 52 (01) : 30 - 35
  • [29] Response to neoadjuvant therapy for rectal cancer: influence on long-term results
    Biondo, S
    Navarro, M
    Marti-Rague, J
    Arriola, E
    Pares, D
    Del Rio, C
    Cambray, M
    Novell, V
    COLORECTAL DISEASE, 2005, 7 (05) : 472 - 479
  • [30] Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer Treatment outcome outside clinical trials
    Winkler, J.
    Zipp, L.
    Knoblich, J.
    Zimmermann, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (05) : 377 - 382